iOnctura to present research on roginolisib and IOA-359 at ASH
- Three abstracts accepted by ASH with two poster presentations
Geneva, Switzerland and Amsterdam, The Netherlands, 3 November 2023 - iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways, today announces abstract data to be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, San Diego, California, from 9-12 December 2023.
Catherine Pickering, Chief Executive Officer of iOnctura, said: “We are excited to present new research for roginolisib and IOA-359 at ASH. These data highlight the progress we are continuing to make in characterising and targeting resistance mechanisms across a variety of malignancies. Complementing our recently published evidence of the synergy between autotaxin and TGF-β inhibition in the treatment of pancreatic cancer; at ASH we will present data on the role of TGF-b inhibition in myeloproliferative disorders. Building on our ongoing clinical investigation of roginolisib in patients with lymphoma, we will also present evidence of the synergy between Bcl-2 and PI3Kδ inhibition in Chronic Lymphocytic Leukemia (CLL).”
Details of the presentations are as follow:
Presentation Title: Novel PI3Kδ Inhibitor Roginolisib Synergizes with the Bcl-2 Inhibitor Venetoclax in Hematological Malignancies
Session Name: 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster III
Session Date: Monday, December 11, 2023
Presentation Time: 6:00 PM - 8:00 PM
Presenter: Dr. Kandathilparambil Sasi
Location: San Diego Convention Center, Halls G-H
Presentation Title: Preclinical Activity of Novel TGF Beta Receptor I Kinase Inhibitors IOA-359 and IOA-360 for Treatment of Anemia in MDS/AML
Session Name: 636. Myelodysplastic Syndromes–Basic and Translational: Poster III
Session Date: Monday, December 11, 2023
Presentation Time: 6:00 PM - 8:00 PM
Presenter: Dr. Charan Vegivinti
Location: San Diego Convention Center, Halls G-H
Abstract Title: Roginolisib a Highly Selective Allosteric Modulator of the Phosphoinositide 3-Kinase Delta (PI3Kδ) in Patients with Refractory/Relapsed Follicular Lymphoma
Author: Dr. Carmelo Carlo-Stella
Publication: November supplemental issue of Blood and will become part of the permanent ASH and Blood Abstracts Archive.
